STOCK TITAN

Zomedica Corp - ZOM STOCK NEWS

Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.

Overview

Zomedica Corp (NYSE American: ZOM) is an innovative veterinary healthcare company dedicated to enhancing animal health through advanced diagnostic and therapeutic solutions. Specializing in point-of-care technologies for companion animals and equines, the company offers a robust portfolio designed to address the unmet needs of clinical veterinarians and improve practice efficiencies. With a focus on novel diagnostic platforms and non-invasive therapeutic devices, Zomedica empowers veterinary professionals to lower operating costs, increase productivity, and ultimately deliver superior patient care.

Product Portfolio and Technological Innovations

Zomedica's offerings include an array of cutting-edge products that integrate advanced imaging, automated diagnostic capabilities, and innovative therapeutic modalities. The company is renowned for its TRUFORMA diagnostic platform, a system that utilizes proprietary sensor technologies for accurate and rapid testing. Alongside this, its digital cytology system and remote monitoring solutions enhance the precision of diagnoses and clinical decision-making. Additionally, Zomedica’s novel therapeutic devices are designed to accelerate healing processes and minimize patient discomfort through non-invasive methods.

Market Position and Competitive Edge

Operating within the broader veterinary health industry, Zomedica has established a strong market position by addressing both clinical and business challenges faced by veterinarians. The company differentiates itself with a deep commitment to research and development, leveraging the insights of practicing veterinary professionals to tailor its product suite. This focus on innovation has allowed Zomedica to not only meet the growing demand for efficient, point-of-care diagnostic tools but also to set new operational standards across veterinary practices. Its comprehensive solutions enable veterinarians to conduct tests quickly and accurately, thereby reducing turnaround times and enhancing patient care.

Operational Excellence and Global Reach

Headquartered in Michigan, Zomedica operates from world-class manufacturing and distribution facilities that underscore its commitment to quality and efficiency. With manufacturing operations in key U.S. regions, the company ensures consistent delivery of high-quality products to its domestic and international markets. Zomedica's strategic partnerships in various regions further complement its mission of expanding access to advanced veterinary care globally. The company’s investments in cleanroom technologies and automated production lines not only enhance manufacturing capacity but also streamline logistics and distribution processes.

Benefits to Veterinary Practices

The integrated solutions offered by Zomedica are specifically designed to improve the workflow and profitability of veterinary practices. By automating complex diagnostic procedures and providing rapid, lab-quality results at the point of care, the company enables veterinarians to focus on delivering improved patient outcomes. Enhanced diagnostic speed, reduced operational costs, and increased efficiency are key factors driving the widespread adoption of Zomedica’s technologies in veterinary clinics across varied market segments.

Commitment to Innovation and Quality Care

Underpinned by the insights of industry experts and built on robust scientific research, Zomedica remains committed to continuous improvement in veterinary care. The company’s strategic focus on innovation, combined with its rigorous quality control measures, supports a wide spectrum of diagnostic and therapeutic applications. This dedication not only bolsters the confidence of veterinary professionals in adopting its technologies but also reinforces the company’s reputation for excellence, expertise, and trustworthiness in the veterinary healthcare industry.

Conclusion

Zomedica Corp stands out as a pioneering force in the veterinary health sector by delivering comprehensive, technology-driven solutions that enhance both clinical outcomes and practice management. Through its innovative product portfolio and strategic operational excellence, Zomedica continues to influence the evolution of veterinary diagnostics and therapeutics, enabling veterinarians to provide top-tier care to companion and equine patients.

Rhea-AI Summary
Zomedica Corp. continues its veterinary education mission through presentations at VMX and WVC meetings. The company aims to expand its reach and educate veterinarians about its diagnostic and therapeutic products for equine and companion animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
Rhea-AI Summary
Zomedica Corp. (NYSE American:ZOM) will be hosting a Virtual Investor Day event to discuss its portfolio of innovative products, manufacturing facilities, recent business developments, and financial position. The event will provide an overview of the company's capabilities and key drivers of future growth, followed by a live question-and-answer session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
conferences
-
Rhea-AI Summary
Zomedica Corp. (NYSE American:ZOM) announced an open letter from CEO Larry Heaton to shareholders regarding the upcoming reverse split vote. The letter encourages shareholders to do their own due diligence and vote FOR the reverse split. The company offers point-of-care diagnostics and therapeutic products for equine and companion animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
Rhea-AI Summary
Zomedica Corp. CEO, Larry Heaton, to participate in fireside chat and one-on-one meetings with investors at Lytham Partners 2024 Investor Select Conference. The webcasted fireside chat will take place at 10:15am ET on Thursday, February 1, 2024, and can be accessed on the Company's website or directly at a provided link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
conferences
-
Rhea-AI Summary
Zomedica Corp. (NYSE American:ZOM) reported record revenue of over $25 million for 2023, marking a 32% increase from 2022. The company expects revenue for the fourth quarter of 2023 to exceed $7 million, driven by strong performance in therapeutic and diagnostic product lines. Cash, cash equivalents, and available-for-sale securities are expected to be over $100 million at December 31, 2023. Zomedica CEO, Larry Heaton, highlighted the company's momentum in 2023, including acquisitions, product launches, and manufacturing improvements. The company introduced formal financial guidance for 2024, expecting revenue in the range of $31 to $35 million, an increase of approximately 40% over 2023. Additionally, Zomedica will seek approval for an 80-1 reverse stock split at a Special Meeting on February 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
-
Rhea-AI Summary
Zomedica Corp. (ZOM) to Host Business Update Call on January 17, 2024, to Discuss Preliminary 2023 Revenue, Cash Position, and Share Consolidation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
conferences
Rhea-AI Summary
Zomedica Corp. (ZOM) announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in awake canine patients treated for musculoskeletal disease. The article was written by Dr. Gina L. Joseph and team at Colorado State University and is available in Frontiers in Veterinary Science. CSU is also evaluating the effectiveness of PulseVet therapy for slowing the progression of canine osteoarthritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none
-
Rhea-AI Summary
Zomedica Corp. (NYSE American: ZOM) announced the commercial launch of three new assays: Canine Pancreatic Lipase (cPL), Cobalamin (B12), and Folate for the TRUFORMA® In-Clinic Biosensor Testing Platform. The company aims to provide faster diagnostic solutions, streamline workflow, and increase practice profitability for veterinarians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.53%
Tags
none
-
Rhea-AI Summary
Zomedica Corp. (NYSE American: ZOM) announced new clinical data supporting new indications for shock wave therapy at the recent meeting of the American Association of Equine Practitioners. The study showed that shock wave therapy successfully treated barrel racing horses with Exercise Induced Pulmonary Hemorrhage (EIPH) and asthmatic horses. The company remains committed to advancing animal care through innovation and research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Zomedica Corp. (ZOM) to attend Noble Capital Markets' 19th Annual Emerging Growth Equity Conference. CEO Larry Heaton to present a Company overview and business update at 2:30 p.m. ET on December 5, 2023. A high-definition video webcast of the presentation will be available the following day on the Company's investor website and as part of a complete catalog of presentations available at Noble Capital Markets' conference website and on Channelchek.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
conferences acquisition

FAQ

What is the current stock price of Zomedica (ZOM)?

The current stock price of Zomedica (ZOM) is $0.0973 as of March 5, 2025.

What is the market cap of Zomedica (ZOM)?

The market cap of Zomedica (ZOM) is approximately 95.3M.

What is the core business of Zomedica Corp?

Zomedica Corp focuses on providing innovative diagnostic and therapeutic solutions for veterinary applications, enhancing care for companion and equine animals.

Which markets does Zomedica serve?

The company serves the veterinary healthcare market with products used in both companion animal and equine practices across domestic and international regions.

What type of products does Zomedica offer?

Zomedica offers a range of point-of-care diagnostic platforms, imaging systems, and therapeutic devices designed to streamline practice workflows and improve patient outcomes.

How does Zomedica differentiate itself in the veterinary industry?

By integrating advanced technology with clinically-driven insights, Zomedica delivers precise, rapid diagnostic results and innovative therapeutic solutions that address critical unmet needs in veterinary practices.

What role does the TRUFORMA diagnostic platform play in their offerings?

The TRUFORMA platform provides automated, high-precision diagnostic capabilities at the point of care, reducing turnaround times and enhancing the accuracy of veterinary diagnostics.

How does Zomedica improve operational efficiencies for veterinary clinics?

Their innovative products automate complex diagnostic processes and streamline clinical workflows, leading to faster decision-making, lower costs, and improved patient care.

Why is Zomedica considered an expert in veterinary healthcare?

The company’s commitment to R&D, its science-backed product innovations, and strategic partnerships with veterinary professionals collectively reinforce its reputation for expertise and trustworthiness in the industry.
Zomedica Corp

NYSE:ZOM

ZOM Rankings

ZOM Stock Data

95.35M
961.51M
1.87%
9.37%
4.63%
Medical Devices
Pharmaceutical Preparations
Link
United States
ANN ARBOR